论文已发表
提 交 论 文
注册即可获取Ebpay生命的最新动态
注 册
IF 收录期刊
以针对病理生理机制为手段的中医药治疗肝细胞癌的研究
Authors Lu J, Liu X, Fan K, Lin X
Received 22 December 2024
Accepted for publication 20 March 2025
Published 8 April 2025 Volume 2025:17 Pages 779—792
DOI http://doi.org/10.2147/CMAR.S513729
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Kattesh Katti
Jialin Lu, Xiaoyu Liu, Kaiyan Fan, Xiaofeng Lin
Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, People’s Republic of China
Correspondence: Xiaofeng Lin, Heilongjiang University of Chinese Medicine, 24 heping Road, Harbin, Heilongjiang, People’s Republic of China, Email 13796633510@163.com
Abstract: Liver cancer is a significant global health concern, with projections indicating that the incidence of morbidity may surpass one million cases by 2025. Hepatocellular carcinoma (HCC) is the predominant subtype of liver cancer, constituting approximately 90% of all liver cancer diagnoses. Infections caused by the hepatitis B virus (HBV) and hepatitis C virus (HCV) are recognized as primary risk factors for the development of HCC. However, non-alcoholic steatohepatitis (NASH), which is often linked to metabolic syndrome or diabetes, is increasingly being recognized as a prevalent risk factor in Western populations. Furthermore, HCC associated with NASH exhibits distinct molecular pathogenesis. Patients diagnosed with HCC have access to a range of therapeutic interventions, including liver transplantation, surgical resection, percutaneous ablation, radiation therapy, and transarterial and systemic therapies. Consequently, effective clinical decision-making requires a multidisciplinary approach to adapt individualized treatment plans based on the patient’s tumor stage, liver function, and overall performance status. The approval of new first- and second-line pharmacological agents, along with the establishment of immune checkpoint inhibitor therapies as standard treatment modalities, has contributed to an improved prognosis for patients with HCC. Nevertheless, the optimal sequencing of these therapeutic agents remains to be elucidated, highlighting the urgent need for predictive biomarkers to inform treatment selections. Traditional Chinese Medicine (TCM) has demonstrated potential as a complementary and alternative therapeutic approach for liver cancer, warranting further investigation. This review aimed to examine the comprehensive treatment of HCC through the lens of TCM, informed by the current understanding of its epidemiology, diagnosis, and pathophysiology.
Keywords: hepatocellular carcinoma, HCC, Wnt signaling pathway, TCM